BioTuesdays

Tag - ACST

Acasti Pharma

Echelon cuts Acasti Pharma to sell; PT to 15 cents

Echelon Wealth Partners downgraded Acasti Pharma (TSXV:ACST) to “sell” from “speculative buy” and slashed its price target to 15 cents (Canadian) from $1.40 after the company reported that its Phase 3 TRILOGY 2 trial...

Acasti Pharma

HCW halves Acasti Pharma PT to $3 from $6

H.C. Wainwright halved its price target for Acasti Pharma (NASDAQ:ACST) to $3 from $6 in light of the continued uncertainty around the company’s TRILOGY 1 and TRILOGY 2 trials. The stock closed at 57 cents on Feb. 14...